Eikon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	88.63	55.81	58.48
Research & Development	250.32	204.54	207.26
Total Operating Expenses	338.95	260.34	265.74
Operating Income	-338.95	-260.34	-265.74
Interest Income	15.57	16.56	23.74
Interest Expense	-0.84	-0.03	-0.04
Other Non-Operating Income (Expense)	-0.03	-0	0.04
Total Non-Operating Income (Expense)	14.7	16.53	23.74
Pretax Income	-324.25	-243.81	-242
Net Income	-324.25	-243.81	-242
Net Income Attributable to Preferred Dividends	9.4	-	-
Net Income to Common	-333.64	-243.81	-242
Shares Outstanding (Basic)	3	3	2
Shares Outstanding (Diluted)	3	3	2
Shares Change (YoY)	14.85%	24.32%	-
EPS (Basic)	-115.29	-96.76	-119.40
EPS (Diluted)	-115.29	-96.76	-119.40
Shares Outstanding	3.07	2.87	2.83
Free Cash Flow	-235.26	-219.6	-219.36
Free Cash Flow Per Share	-81.29	-87.16	-108.23
EBITDA	-320.07	-245.34	-254.31
EBIT	-338.95	-260.34	-265.74

SEC Filings: 10-K · 10-Q